tiprankstipranks
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
US Market

Cyclo Therapeutics (CYTH) Income Statement

189 Followers

Cyclo Therapeutics Income Statement

Last quarter (Q4 2023), Cyclo Therapeutics's total revenue was $311.40K, an increase of 66.70% from the same quarter last year. In Q4, Cyclo Therapeutics's net income was $-5.64M. See Cyclo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 1.08M$ 1.08M$ 1.38M$ -122.83K$ 903.38K$ 1.01M
Cost of Revenue
$ -40.52K$ 84.37K$ -24.08K$ 185.12K$ 66.40K$ 75.49K
Gross Profit
$ 964.52K$ 992.04K$ 1.40M$ -185.12K$ 836.98K$ 931.71K
Operating Expense
$ 10.80M$ 21.02M$ 16.83M$ 15.57M$ 9.80M$ 8.32M
Operating Income
$ -9.93M$ -20.05M$ -15.62M$ -15.75M$ -8.96M$ -7.39M
Net Non Operating Interest Income Expense
---$ 3.40K--
Other Income Expense
$ -145.17K$ 7.25K$ -171.00K$ -1.46M$ 18.53K$ -141.75K
Pretax Income
$ -20.06M$ -20.06M$ -15.45M$ -14.29M$ -8.94M$ -7.53M
Tax Provision
---$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -9.83M$ -20.06M$ -15.45M$ -14.29M$ -8.94M$ -7.53M
Basic EPS
$ -1.23$ -1.23$ -1.83$ -2.24$ -5.60$ -7.00
Diluted EPS
$ -1.23$ -1.23$ -1.83$ -2.24$ -5.60$ -7.00
Basic Average Shares
$ 65.32M$ 16.33M$ 8.44M$ 6.37M$ 1.60M$ 1.08M
Diluted Average Shares
$ 65.32M$ 16.33M$ 8.44M$ 6.37M$ 1.60M$ 1.08M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.81M$ 21.01M$ 16.81M$ 15.75M$ 9.86M$ 8.40M
Net Income From Continuing And Discontinued Operation
$ -20.06M$ -20.06M$ -15.45M$ -14.29M$ -8.94M$ -7.53M
Normalized Income
$ -11.89M$ -15.85M--$ -8.96M$ -7.39M
Interest Expense
------
EBIT
$ -20.06M$ -20.05M$ -15.45M$ -14.29M$ -8.96M$ -7.39M
EBITDA
$ -15.42M$ -20.03M$ -15.43M$ -14.28M$ -8.95M$ -7.39M
Currency in USD

Cyclo Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis